AOD9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Research and contributions === Laposata is the author of Laposata's Laboratory Medicine: Diagnosis of Disease in the Clinical Laboratory (McGraw Hill), now in its fourth edition.[2] He has published more than 200 peer-reviewed papers focusing on fatty acid metabolism and diagnostic studies in coagulation.[2] As an expert in bleeding and clotting disorders that can mimic child abuse, his testimony has been reported to have contributed to exonerations and to children being returned to their families.[3]
=== Halogenation === Direct difluoromethylation via Zn(SO2CF2H)2 N–X Anomeric Amides as Electrophilic Halogenation Reagents (2023) Guanidine-based chlorinating reagent, CBMG or "Palau'chlor" (2014) Regioselective bromination of N-oxides (2013)
==== Australia ==== Diazepam is a Schedule 4 substance under the Poisons Standard (June 2018). A Schedule 4 drug is outlined in the Poisons Act 1964 as, "Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription".
Chorley councillor Craige Southern is convicted of assault. 14 March – Labour chooses Karen Shore, the deputy leader of Cheshire West and Chester Council to contest the 2025 Runcorn and Helsby by-election. A hearing at the Old Bailey sets a trial date of 29 June 2026 for Nathan Gill, who is accused of accepting bribes to make statements in the European Parliament that would have been beneficial to Russia. The High Court rules that former Home Secretary Suella Braverman acted unlawfully by housing three asylum seekers at MDP Wethersfield in Essex between July 2023 and February 2024, where they lived in "prison like" conditions. 17 March – King Charles III meets newly appointed Canadian Prime Minister Mark Carney at Buckingham Palace. Reform UK leader Nigel Farage welcomes a further 29 councillors, who have defected to the party in recent weeks. The Refugee Council report that almost 42,000 asylum seekers are waiting for an appeal hearing after the Home Office. 18 March – A crackdown on government-funded credit cards is announced, with plans to reduce the 20,000 estimated to be in circulation by 50%. 19 March – King Charles III and Queen Camilla pay an official visit to Northern Ireland, which includes a private meeting with the First and Deputy First Ministers. 20 March – Private WhatsApp messages are revealed in which Reform UK leader Nigel Farage accuses Rupert Lowe of "damaging the party just before elections" following a Daily Mail article in which he described Reform as being a "protest party" led by "the Messiah".
Even if submerging them in a desiccant were more effective than leaving them to dry in open air, common desiccants such as silica gel or cat litter are better than rice. Mobile phones do not create considerable electromagnetic interference when used in hospitals. The Apple logo was not inspired by Alan Turing or his death by cyanide-laced apple. Although Turing was found dead with a half-eaten apple near his bed in 1954 and was a key figure in computing history, Apple's logo designer Rob Janoff has repeatedly denied any connection.
Sources: en.wikipedia.org
=== Private and public key generation === A cryptocurrency wallet works by random number being generated. The number is converted to a private key using the specific requirements of the cryptocurrency. A public key is then generated from the private key. This private key is used by the owner to access and send cryptocurrency, while the public key can be shared to any third party to receive cryptocurrency. Up to this stage no computer or electronic device is required and all key pairs can be mathematically derived and written down by hand. The private key and public key pair (known as an address) are not known by the blockchain or anyone else. The blockchain will only record the transaction of the public address when cryptocurrency is sent to it, thus recording in the blockchain ledger the transaction of the public address.
=== Special edition === On June 26, 2007, Stone Sour released a special edition version of the album with six previously unreleased tracks and a bonus DVD. The DVD included a full concert performance by the band from October 2006 in Moscow and the music videos for "30/30-150", "Through Glass", and "Sillyworld". When talking about the special edition, vocalist Taylor said, "We really wanted to do something which was really cool," saying that it shows the band's different musical elements and them in their live element, which he says "people really gravitate towards". In addition to this, Stone Sour released a live album of their concert in Moscow exclusively on iTunes, entitled Live in Moscow.
Radioactive primordial nuclides found in the Earth are residues from ancient supernova explosions that occurred before the formation of the Solar System. They are the fraction of radionuclides that survived from that time, through the formation of the primordial solar nebula, through planet accretion, and up to the present time. The naturally occurring short-lived radiogenic radionuclides found in today's rocks, are the daughters of those radioactive primordial nuclides. Another minor source of naturally occurring radioactive nuclides are cosmogenic nuclides, that are formed by cosmic ray bombardment of material in the Earth's atmosphere or crust. The decay of the radionuclides in rocks of the Earth's mantle and crust contribute significantly to Earth's internal heat budget.
Cells receive information from their neighbors through a class of proteins known as receptors. Receptors may bind with some molecules (ligands) or may interact with physical agents like light, mechanical temperature, pressure, etc. Reception occurs when the target cell (any cell with a receptor protein specific to the signal molecule) detects a signal, usually in the form of a small, water-soluble molecule, via binding to a receptor protein on the cell surface, or once inside the cell, the signaling molecule can bind to intracellular receptors, other elements, or stimulate enzyme activity (e.g. gasses), as in intracrine signaling. Signaling molecules interact with a target cell as a ligand to cell surface receptors, and/or by entering into the cell through its membrane or endocytosis for intracrine signaling. This generally results in the activation of second messengers, leading to various physiological effects. In many mammals, early embryo cells exchange signals with cells of the uterus. In the human gastrointestinal tract, bacteria exchange signals with each other and with human epithelial and immune system cells. For the yeast Saccharomyces cerevisiae during mating, some cells send a peptide signal (mating factor pheromones) into their environment. The mating factor peptide may bind to a cell surface receptor on other yeast cells and induce them to prepare for mating.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.